CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 34 enrolled
Drug / intervention
Paclitaxel + Carboplatin + CP-870,893 +1 moredrug
Likely dose
Paclitaxel + Carboplatin + CP-870,893 175 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00607048
NCT00607048Phase 1Completed
CompareCT.gov

A Phase 1 Study Of CP- 870,893 In Combination With Paclitaxel And Carboplatin In Patients With Metastatic Solid Tumors

Hoffmann-La Roche·interventional·Posted Feb 5, 2008·Updated Mar 27, 2017

In Brief

A Phase 1 clinical trial evaluating Paclitaxel + Carboplatin + CP-870,893 for Neoplasms. Completed, enrolled 34 participants across 4 sites.

Detailed Summary

This is a dose-finding study; therefore, there is no hypothesis testing

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 5, 2008
Enrollment StartNov 1, 2007
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.4 years ago

Interventions

Paclitaxel + Carboplatin + CP-870,893drug

Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)

Paclitaxel + Carboplatin + CP-870,893drug

Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)